Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Buckle G, Bandari D, Greenstein J, Gudesblatt M, Khatri B, Kita M, Repovic P, Riser E, Weinstock-Guttman B, Thrower B, Loring S, Riester K, Everage N, Prada C, Koulinska I, Mann M. Buckle G, et al. Among authors: riester k. Mult Scler J Exp Transl Clin. 2020 Apr 29;6(2):2055217320918619. doi: 10.1177/2055217320918619. eCollection 2020 Apr-Jun. Mult Scler J Exp Transl Clin. 2020. PMID: 32440353 Free PMC article.
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, Riester K, Mendoza JP, Livingston T, Jhaveri M. Ontaneda D, et al. Among authors: riester k. Mult Scler Relat Disord. 2019 Jan;27:101-111. doi: 10.1016/j.msard.2018.09.038. Epub 2018 Oct 10. Mult Scler Relat Disord. 2019. PMID: 30368221 Free article.
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, Zhu B. Chang I, et al. Among authors: riester k. Mult Scler. 2022 Dec;28(14):2263-2273. doi: 10.1177/13524585221114997. Epub 2022 Sep 21. Mult Scler. 2022. PMID: 36131595 Free PMC article. Clinical Trial.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J. Kappos L, et al. Among authors: riester k. N Engl J Med. 2015 Oct 8;373(15):1418-28. doi: 10.1056/NEJMoa1501481. N Engl J Med. 2015. PMID: 26444729 Free article. Clinical Trial.
Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP, Zhang Y, Riester K, Tang MT, Efros L, Shi J, Harris J, Vexler V, Elkins JS. Sheridan JP, et al. Among authors: riester k. Mult Scler. 2011 Dec;17(12):1441-8. doi: 10.1177/1352458511414755. Epub 2011 Aug 1. Mult Scler. 2011. PMID: 21807759 Clinical Trial.
32 results